{'fraction_non_alphanumeric': 0.039097744360902256, 'fraction_numerical': 0.018796992481203006, 'mean_word_length': 5.429951690821256, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
360 Novel immunotherapy for prostate cancer combining CAR T cells and myeloid cell STAT3 inhibition

Background Poor prognosis for patients with metastatic castra-tion resistant prostate cancer (mCRPC) has inspired efforts to develop effective treatments for advanced disease. Our lab has developed a chimeric antigen receptor (CAR)-engineered T cell targeting prostate stem cell antigen (PSCA), which is overex-pressed in a majority of primary and metastatic prostate can-cers. We believe PSCA-CAR T cells will provide a safe and effective strategy for improving clinical outcomes for mCRPC patients. While encouraged by clinical activity in our phase 1 trial (NCT03873805), the immunosuppressive tumor microen-vironment (TME) will limit therapeutic potential. Central to tumor/immune cell interactions is the transcription factor, sig-nal transduction and activation of transcription-3 (STAT3), recognized for its critical role in regulating multiple tumor-associated myeloid cell-related genes known to suppress anti-tumor immunity, including type-I IFNs, IL-10, IL-12, TGF b , and PD-L1. Thus, we hypothesized that TME modulation with a TLR9-guided STAT3 anti-sense oligonucleotide CpG-STAT3ASO (CSI3) would provide myeloid cell-selective STAT3 inhibition, which combined with PSCA-CAR T cells will improve responses in mCRPC.